μ-Opioid Receptor Gene A118G Polymorphism Predicts Survival in Patients with Breast Cancer

• DOI: 10.1097/aln.0b013e31824b96a1
• Publication Date: 2012-03-22T19:49:35Z
• Authors: Andrey V. Bortsov; Robert C. Millikan; Inna Belfer; Richard L. Boortz...; Harendra Arora; Samuel A. McLean
• Keywords: Adult; Male; Gene Dosage; Receptors, Opioid, mu; Breast Neoplasms; Middle Aged; Polymorphism, Single Nucleotide; 3. Good health; Cohort Studies; Survival Rate; Young Adult; Amino Acid Substitution; Predictive Value of Tests; Case-Control Studies; Humans; Female; Aged; Follow-Up Studies

Background Preclinical studies suggest that opioids may promote tumor growth. Genetic polymorphisms have been shown to affect opioid receptor function and modify the clinical effects of morphine. In this study we assessed association between six common in μ-opioid gene, including well known A118G polymorphism, breast cancer survival. Methods A total 2,039 women ages 23-74 yr (38% African-American, 62% European-American, 55% postmenopausal) diagnosed with 1993-2001 were followed through 2006. Genotyping was performed using TaqMan platform (Applied Biosystems Inc., Foster City, CA). Kaplan-Meier curves, log-rank tests, Cox proportional hazard models used examine each genotype Results After Bonferroni correction for multiple testing, patient at associated cancer-specific mortality 10 yr. Women one or more copies G allele had decreased (P < 0.001). This limited invasive cases only; effect size appeared increase stage. regression model adjusted age ethnicity also showed A/G G/G genotypes compared A/A (hazard ratio = 0.57 [0.38, 0.85] 0.32 [0.22, 0.49], respectively; P 0.006). Conclusions These results pathways be involved Further examining genetic variants influencing system survival are warranted.